UPDATE Hematology / Oncology 2024
ESMO Congress 2023
Patients with metastatic or inoperable breast cancer benefit from antibody-drug conjugates. Amivantamab combinations are emerging as new options for EGFR mutated advanced NSCLC. Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer patients who are taxane naive. Digital health technologies are revolutionising cancer care.
You're using a very old browser version. Some of the features of this page might not display properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts, ePosters, and more.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterPatients with metastatic or inoperable breast cancer can benefit from antibody-drug conjugates.23 Oct 2023Datopotamab Deruxtecan and Trastuzumab Deruxtecan Shown to Be Effective in Breast Cancer with HER2-non-Amplification.
Datopotamab Deruxtecan and Trastuzumab Deruxtecan Shown to Be Effective in Breast Cancer with HER2-Non-Amplification.
Daily ReporterCombination therapies with amivantamab are now available for advanced NSCLC mutated by EGFR.23 Oct 2023The MARIPOSA-2 and MARIPOSA phase III trials reported clinically meaningful improvements in first and second-line treatment compared to standard care.
Register for tickets or booths
Venue Map and Hotels Around
Munich - Holiday Inn Munich - City Centre, Bavaria, Germany Munich - Holiday Inn Munich - City Centre, Bavaria, Germany
Subscribe